immunoclin.com
ImmunoClin Corporation (IMCL) Relocates European Headquarters and Laboratories to London, UK
http://www.immunoclin.com/index.php/news/immunoclin-news/57-immunoclin-corporation-imcl-relocates-european-headquarters-and-laboratories-to-london-uk
ImmunoClin Corporation (IMCL) Relocates European Headquarters and Laboratories to London, UK. March 10, 2015. To the United Kingdom. And has established its laboratories at the London Bioscience Innovation Centre (LBIC) in Central London. ImmunoClin's corporate headquarters continue to be based in Washington, DC. Director and Chief Scientific Officer of ImmunoClin Corporation. LBIC is owned and operated by the Royal Veterinary College, an independent college of the University of London. It is a pleasure ...
immunoclin.com
Subsidiary of ImmunoClin Corporation (IMCL) Receives Controlled Drug License in the United Kingdom
http://www.immunoclin.com/index.php/news/immunoclin-news/58-subsidiary-of-immunoclin-corporation-imcl-receives-controlled-drug-license-in-the-united-kingdom
Subsidiary of ImmunoClin Corporation (IMCL) Receives Controlled Drug License in the United Kingdom. April 2, 2015. PRNewswire/ - ImmunoClin Corporation (OTC Markets: IMCL), a healthcare company specialized in personalized medicine, announces that its wholly owned subsidiary, ImmunoClin Ltd., received a controlled drug license from the UK government to possess, supply and produce schedule 1 drugs in its UK laboratory. CEO and President of ImmunoClin Corporation. ImmunoClin concentrates its innovation on d...
immunoclin.com
About IMCL
http://www.immunoclin.com/index.php/company
ImmunoClin Corporation is a United States healthcare company with principal office in Washington DC, European headquarters and laboratories in central London, United Kingdom. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer’s disease.
immunoclin.com
ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech
http://www.immunoclin.com/index.php/news/immunoclin-news/59-immunoclin-ltd-to-provide-cro-services-for-crotoxin-clinical-trials-for-celtic-biotech
ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech. Dr Paul Reid, President of Celtic Biotech, said "ImmunoClin's team has formidable experience in the oncology field and they offer unparalleled clinical development expertise. We look forward to working with them.". About Spotlight Innovation Inc. About Celtic Biotech Iowa, Inc. About the ImmunoClin Corporation. ImmunoClin Corporation (OT...
immunoclin.com
Products Overview
http://www.immunoclin.com/index.php/products/products-overview
Learn more about the exciting lead products of ImmunoClin. Multi-Variant Atherosclerosis Risk Assessment (MARA ). Genetic Alzheimer’s Risk Discovery (GARD ). PRIMALEUKIN : Broad Spectrum Anti-Infective Therapy. Commonly known as interleukin-22 (IL-22), has a unique position as a combined antibacterial, anti-fungal and antiviral agent, harnessing and amplifying the body’s own natural defense against, and recovery from infection and as such has a potential to be targeted against several indications and com...
immunoclin.com
SEC Filings
http://www.immunoclin.com/index.php/corporate/sec-filings
April 21-23, 2016 Dubai, United Arab Emirates. 6th Global Experts Meeting and Expo on Nanomaterials and Nanotechnology. August 21-26, 2016 Melbourne, Australia. International Congress of Immunology. August 22-25, 2016 in Sendai City, Miyagi, Japan. 16th International Conference on Nanotechnology: Green Nanotechnology for a. October 3-5, 2016, London, United Kingdom. 4th International Conference on Geriatrics and Gerontology. October 9-10, 2016 Dubai, United Arab Emirates. June 21-22, 2017, Vienna, Austria.
immunoclin.com
Current Share Structure
http://www.immunoclin.com/index.php/corporate/current-share-structure
Company Stock Symbol (OTC). IMCL - View Stock Quote. AUTHORIZED SHARES : 300,000,000. Common: 290,000,000. Preferred: 9,000,000. Preferred, Series A: 1,000,000. SHARES ISSUED and OUTSTANDING. Common: 47,413,793. Preferred, Series A: 1,000,000. Action Stock Transfer Corporation. 2469 E. Fort Union Boulevard. Salt Lake City, UT 84121. Phone: 1 (801) 274-1088. Fax: 1 (801) 274-1099. Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 19th International Confere...
immunoclin.com
GARD™
http://www.immunoclin.com/index.php/products/genetic-alzheimer-s-risk-discovery-gard
Genetic Alzheimer’s Risk Discovery (GARD ). The e4 allele of the APOE gene is the strongest genetic risk factor for late-onset Alzheimer’s disease; people with two ApoE4 copies have a 25-fold increased risk for developing the disease compared to ApoE3/ApoE3 carriers. Certain combinations of IL-10 and IL-6 polymorphisms can increase risk 10-fold. Test detects multiple genetic polymorphisms including ApoE, IL-6 and IL-10, all associated with increased risk of late-onset Alzheimer’s Disease. August 21-26, 2...
immunoclin.com
ImmunoClin News
http://www.immunoclin.com/index.php/news/immunoclin-news
Spotlight Innovation subsidiary Celtic Biotech prepares to start Part 2 of Phase I Intravenous Crotoxin clinical study post completion of Part 1. ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech. Subsidiary of ImmunoClin Corporation (IMCL) Receives Controlled Drug License in the United Kingdom. ImmunoClin Corporation (IMCL) Relocates European Headquarters and Laboratories to London, UK.
SOCIAL ENGAGEMENT